Proton Reirradiation for High-Risk Recurrent or New Primary Breast Cancer
Cancers · 06.12.2023 · 15 (24) · 5722
DOI: 10.3390/cancers15245722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.12.2023. Verfasst von Molly A Chakraborty und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers New Jersey Medical School, Newark, NJ 07103, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH/NCI Memorial Sloan Kettering Cancer Center Support Grant/Core.
Abstract (Originalsprache)
Radiotherapy is an integral component of multidisciplinary breast cancer care. Given how commonly radiotherapy is used in the treatment of breast cancer, many patients with recurrences have received previous radiotherapy. Patients with new primary breast cancer may also have received previous radiotherapy to the thoracic region. Curative doses and comprehensive field photon reirradiation (reRT) have often been avoided in these patients due to concerns for severe toxicities to organs-at-risk (OARs), such as the heart, lungs, brachial plexus, and soft tissue. However, many patients may benefit from definitive-intent reRT, such as patients with high-risk disease features such as lymph node involvement and dermal/epidermal invasion. Proton therapy is a potentially advantageous treatment option for delivery of reRT due to its lack of exit dose and greater conformality that allow for enhanced non-target tissue sparing of previously irradiated tissues. In this review, we discuss the clinical applications of proton therapy for patients with breast cancer requiring reRT, the currently available literature and how it compares to historical photon reRT outcomes, treatment planning considerations, and questions in this area warranting further study. Given the dosimetric advantages of protons and the data reported to date, proton therapy is a promising option for patients who would benefit from the added locoregional disease control provided by reRT for recurrent or new primary breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Radiation Oncology, New York University, New York, NY 10016, USA.
- New York Proton Center, New York, NY 10035, USA.
ORCID-Profile: Molly A Chakraborty
Förderung
- NCI NIH HHS
- NIH HHS
- NIH/NCI Memorial Sloan Kettering Cancer Center Support Grant/Core
Zitieren
APA
Chakraborty, M. A., Khan, A. J., Cahlon, O., Xu, A. J., Braunstein, L. Z., Powell, S. N., & Choi, J. I. (2023). Proton Reirradiation for High-Risk Recurrent or New Primary Breast Cancer. Cancers, 15(24), 5722. https://doi.org/10.3390/cancers15245722
Vancouver
Chakraborty MA, Khan AJ, Cahlon O, Xu AJ, Braunstein LZ, Powell SN, et al. Proton Reirradiation for High-Risk Recurrent or New Primary Breast Cancer. Cancers. 2023;15(24):5722. doi:10.3390/cancers15245722
BibTeX
@article{Chakraborty2023,
author = {Chakraborty, Molly A and Khan, Atif J and Cahlon, Oren and Xu, Amy J and Braunstein, Lior Z and Powell, Simon N and Choi, J Isabelle},
title = {Proton Reirradiation for High-Risk Recurrent or New Primary Breast Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {24},
pages = {5722},
doi = {10.3390/cancers15245722}
}
EUVIMED